ClinicalTrials.gg
CompletedNCT01081678STARTT-HipUpdated Sep 21, 2022Results posted

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

A Phase 2 interventional study of Placebo and Romosozumab in Fracture Healing, sponsored by Amgen. Completed at 99 sites in 24 countries. Open to participants aged 55 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
55 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.

Enrollment
16th of 105
332 · median 64
Started
2010
the only one that year
Phase 2
16 of 133
none open now
Registered
29th of 133
by date

Among the 133 studies in Hip Fractures with a site in United States, this one is the 16th largest by enrollment of the 105 interventional ones that give a count, is the only one that started in 2010, is one of 16 in phase 2, and was the 29th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 55 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Hip Fractures with a site in United States, or all of them as a file.
02

Study summary

This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.

03

Conditions studied

  • Fracture Healing

Browse trials for

Keywords

  • AMG 785
  • Proximal Femur
  • Fracture Healing
  • Hip Fracture
04

Who can participate

Ages eligible
55 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, age 55 to 95 years
  • fresh unilateral low energy intertrochanteric or femoral neck fracture as the primary injury, confirmed by X-ray and in the opinion of the treating surgeon amenable to repair by internal fixation
  • internal fixation of the fracture with devices approved by local regulatory agency, performed no later than 7 days after injury for intertrochanteric or undisplaced femoral neck fractures and no later than 2 days after injury for displaced femoral neck fractures

    • intertrochanteric fracture: sliding hip screw or IM nail
    • femoral neck fracture: sliding hip screw or at least 3 cancellous screws

Exclusion criteria

Exclusion Criteria:

  • severe symptomatic osteoarthritis of the lower extremity
  • inability to independently rise from armchair or walk 200 meters before hip fracture
  • presence of concomitant injuries such as rib fractures, wrist fractures, or acute symptomatic vertebral fractures which severely impair the ability to rise from a chair
  • associated extremity injuries including ipsilateral or contralateral fractures of the foot, tibia or fibula, wrist, humerus, femoral shaft, femoral head or hip dislocation, that may delay weight-bearing beyond one week after surgery
  • head-injury, as defined by Glasgow Coma Scale \< 13 prior to randomization
  • use of bone grafts or bone substitutes at the time of fracture fixation
  • major polytrauma or significant axial trauma, with Injury Severity Score > 16
  • pathological fracture or history of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of the results, such as Paget's disease, rheumatoid arthritis, osteomalacia, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia
  • history of symptomatic spinal stenosis that has not been surgically corrected. If surgically corrected, the subject must be asymptomatic to be eligible for the study.
  • history of facial nerve paralysis
  • (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical carcinoma in situ) within the last 5 years
  • history of solid organ or bone marrow transplants
  • evidence of elevated transaminases (≥ 2.0 x ) or significantly impaired renal function ( of ≤ 30 mL/min)
  • evidence of current hypercalcemia or hypocalcemia (outside of 1.1 x the normal range)
  • bone morphogenic proteins (BMP)-2 or BMP-7 at the time of definitive fracture fixation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.

    Drug: Placebo

  • Experimental
    Romosozumab 70 mg

    Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.

    Drug: Romosozumab

  • Experimental
    Romosozumab 140 mg

    Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.

    Drug: Romosozumab

  • Experimental
    Romosozumab 210 mg

    Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.

    Drug: Romosozumab

Interventions

  • DrugPlacebo

    Administered by subcutaneous (under the skin) injection

  • Administered by subcutaneous injection

    Also known as: AMG 785, Evenity

06

What researchers measure

Primary outcomes

  1. Timed-Up-and-Go (TUG) Over Week 6 Through Week 20

    Functional healing was measured by the timed-up-and-go test (TUG) over Weeks 6 through 20. During this assessment, the clinician timed the participant while they stood up from a seated position in a chair, walked three meters, turned around, walked three meters back to the chair, and returned to the seated position. A TUG value of ten seconds or less was considered normal for a healthy elderly person. Higher TUG values after hip fracture have been shown to be a predictor of future falls. Least squares mean (LSM) estimates were based on a repeated measures model fitted with the log-transformed TUG values at weeks 2, 6, 12, 16, 20, 24, 36, 52 as the dependent variable and adjusted for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction and back-transformed using the exponential transformation.

    Time frame: Weeks 6, 12, 16, and 20

Secondary outcomes

  1. Timed-Up-and-Go (TUG) at Each Visit

    During the timed-up-and-go test the clinician timed the participant while they stood up from a seated position in a chair, walked 3 meters, turned around, walked 3 meters back to the chair, and returned to a seated position. A TUG value of ≤ 10 seconds is considered normal for a healthy elderly person. LSMs were based on a repeated measures model adjusting for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction. Missing TUG values for participants still on study were imputed using the last observation carried forward (LOCF) when possible. If no observation could be carried forward, the maximum TUG value observed among all participants at a given visit was used. TUG values obtained after unplanned revision surgery were replaced by carrying forward the last available observed or imputed value prior to unplanned revision surgery.

    Time frame: Weeks 2, 6, 12, 16, 20, 24, 36, and 52

  2. Time to Radiographic Healing

    Time to radiographic healing is the time interval from the surgery date for the eligible hip fracture to the date of radiographic healing, defined as effacement of the fracture lines by newly formed bone along the cortices and within the trabecular bone on anteroposterior and lateral (or oblique) radiographs. Radiographic fracture healing was determined by a panel of independent reviewers blinded to treatment. The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.

    Time frame: 52 weeks

  3. Radiographic Union Scale for Hip (RUSH) Score At Each Visit

    The radiographic Union Scale for Hip (RUSH) is a semiquantitative scoring assessment to assess hip fracture healing after surgical repair. The RUSH has 4 key domains based on radiographic parameters used by orthopedic surgeons and radiologists in routine clinical practice including cortical bridging (4 to 12 points), cortical fracture line disappearance (4 to 12 points), trabecular consolidation (1 to 3 points), and trabecular index disappearance of fracture line (1 to 3 points). The score has a minimum of 10 points (definitely not healed) and a maximum of 30 points (definitely healed).

    Time frame: Weeks 2, 6, 12, 16, 20, 24, 36, and 52

  4. Harris Hip Score At Each Visit

    The Harris Hip Score is a clinician-based outcome that assesses pain, function, deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities and gait. Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. The score ranges form 0-100 (best possible outcome) covering pain (0-44 points), function (0-47 points), absence of deformity (4 points), and range of motion (5 points). LSMs were based on a repeated measures model fitted with the Harris hip score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.

    Time frame: Weeks 2, 6, 12, 16, 20, 24, 36, and 52

  5. Hip Pain Score at Each Visit

    Hip pain was assessed using a visual analog scale (VAS). Participants were asked to rate their pain as a result of the hip fracture on a 100 mm vertical scale with 0 indicating no pain at all and 100 indicating the worst pain they could imagine. LSMs were based on a repeated measures model fitted with hip pain score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.

    Time frame: Weeks 2, 6, 12, 16, 20, 24, 36, and 52

07

Results

Posted May 2, 2019

Participant flow

This study was conducted at 63 centers in 22 countries in Eastern Europe, Western Europe, India, North America, Latin America, Australia, New Zealand and Hong Kong.

Participant flow — Overall Study
MilestonePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Started89609390
Received study drug87608989
Completed 24 weeks of study73507268
Completed62446261
Not completed27163129
Withdrew: Ineligibility determined0011
Withdrew: Noncompliance3452
Withdrew: Adverse event2122
Withdrew: Withdrawal by subject1571714
Withdrew: Administrative decision1001
Withdrew: Lost to follow-up4143
Withdrew: Death2226
Withdrew: Other0100

Outcome measures

PrimaryTimed-Up-and-Go (TUG) Over Week 6 Through Week 20

Functional healing was measured by the timed-up-and-go test (TUG) over Weeks 6 through 20. During this assessment, the clinician timed the participant while they stood up from a seated position in a chair, walked three meters, turned around, walked three meters back to the chair, and returned to the seated position. A TUG value of ten seconds or less was considered normal for a healthy elderly person. Higher TUG values after hip fracture have been shown to be a predictor of future falls. Least squares mean (LSM) estimates were based on a repeated measures model fitted with the log-transformed TUG values at weeks 2, 6, 12, 16, 20, 24, 36, 52 as the dependent variable and adjusted for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction and back-transformed using the exponential transformation.

Time frame:
Weeks 6, 12, 16, and 20
Reported as:
Least squares mean · seconds
Timed-Up-and-Go (TUG) Over Week 6 Through Week 20
secondsPlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 654.1 (44.4 to 66.0)41.0 (32.4 to 51.9)47.2 (38.9 to 57.4)53.3 (43.8 to 64.8)
Week 1229.8 (25.3 to 35.2)27.6 (22.7 to 33.5)30.0 (25.6 to 35.2)36.1 (30.7 to 42.5)
Week 1626.2 (22.2 to 30.8)23.3 (19.2 to 28.3)26.9 (23.0 to 31.6)31.8 (27.1 to 37.4)
Week 2023.8 (20.3 to 28.0)21.9 (18.1 to 26.6)22.9 (19.5 to 26.8)29.1 (24.8 to 34.2)
Statistical analysis
  • Placebo vs Romosozumab 70 mg vs Romosozumab 140 mg vs Romosozumab 210 mg · F-test · p = 0.1983The p-value is based on F-test of multi-linear contrasts at Week 6 through Week 20.
SecondaryTimed-Up-and-Go (TUG) at Each Visit

During the timed-up-and-go test the clinician timed the participant while they stood up from a seated position in a chair, walked 3 meters, turned around, walked 3 meters back to the chair, and returned to a seated position. A TUG value of ≤ 10 seconds is considered normal for a healthy elderly person. LSMs were based on a repeated measures model adjusting for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction. Missing TUG values for participants still on study were imputed using the last observation carried forward (LOCF) when possible. If no observation could be carried forward, the maximum TUG value observed among all participants at a given visit was used. TUG values obtained after unplanned revision surgery were replaced by carrying forward the last available observed or imputed value prior to unplanned revision surgery.

Time frame:
Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Reported as:
Least squares mean · seconds
Timed-Up-and-Go (TUG) at Each Visit
secondsPlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 2132.3 (111.0 to 153.6)119.3 (94.2 to 144.4)121.7 (101.0 to 142.5)129.8 (108.9 to 150.7)
Week 692.4 (74.9 to 109.9)69.5 (48.6 to 90.4)80.3 (63.1 to 97.5)86.7 (69.3 to 104.0)
Week 1247.4 (37.6 to 57.1)39.1 (27.4 to 50.7)44.6 (35.1 to 54.1)56.3 (46.6 to 65.9)
Week 1643.1 (34.1 to 52.1)31.6 (20.9 to 42.4)39.7 (30.9 to 48.6)50.1 (41.2 to 59.1)
Week 2036.4 (28.3 to 44.6)31.0 (21.2 to 40.7)35.1 (27.1 to 43.1)45.6 (37.5 to 53.8)
Week 2433.3 (25.8 to 40.7)28.9 (20.1 to 37.8)31.7 (24.4 to 39.0)40.9 (33.5 to 48.4)
Week 3632.4 (25.1 to 39.7)26.3 (17.5 to 35.0)29.8 (22.5 to 37.0)38.7 (31.3 to 46.0)
Week 5228.7 (22.2 to 35.1)22.8 (15.2 to 30.5)28.8 (22.5 to 35.2)36.3 (29.8 to 42.7)
SecondaryTime to Radiographic Healing

Time to radiographic healing is the time interval from the surgery date for the eligible hip fracture to the date of radiographic healing, defined as effacement of the fracture lines by newly formed bone along the cortices and within the trabecular bone on anteroposterior and lateral (or oblique) radiographs. Radiographic fracture healing was determined by a panel of independent reviewers blinded to treatment. The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.

Time frame:
52 weeks
Reported as:
Median · weeks
Time to Radiographic Healing
weeksPlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Time to Radiographic Healing16.4 (15.3 to 20.1)16.9 (12.9 to 20.3)16.6 (13.3 to 17.1)16.9 (13.3 to 20.9)
SecondaryRadiographic Union Scale for Hip (RUSH) Score At Each Visit

The radiographic Union Scale for Hip (RUSH) is a semiquantitative scoring assessment to assess hip fracture healing after surgical repair. The RUSH has 4 key domains based on radiographic parameters used by orthopedic surgeons and radiologists in routine clinical practice including cortical bridging (4 to 12 points), cortical fracture line disappearance (4 to 12 points), trabecular consolidation (1 to 3 points), and trabecular index disappearance of fracture line (1 to 3 points). The score has a minimum of 10 points (definitely not healed) and a maximum of 30 points (definitely healed).

Time frame:
Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Reported as:
Mean · units on a scale
Radiographic Union Scale for Hip (RUSH) Score At Each Visit
units on a scalePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 212.1 ± 3.312.7 ± 3.512.1 ± 3.412.0 ± 3.1
Week 618.1 ± 3.618.0 ± 4.218.4 ± 3.418.3 ± 4.0
Week 1223.3 ± 4.622.8 ± 4.822.9 ± 4.822.3 ± 5.3
Week 1625.6 ± 4.325.7 ± 4.525.5 ± 5.025.5 ± 4.7
Week 2026.8 ± 4.127.3 ± 4.127.4 ± 4.026.4 ± 4.6
Week 2427.8 ± 3.427.8 ± 3.928.3 ± 3.527.3 ± 3.9
Week 3628.7 ± 2.628.3 ± 3.629.1 ± 2.128.2 ± 3.5
Week 5229.4 ± 2.028.5 ± 3.829.6 ± 1.828.7 ± 3.3
SecondaryHarris Hip Score At Each Visit

The Harris Hip Score is a clinician-based outcome that assesses pain, function, deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities and gait. Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. The score ranges form 0-100 (best possible outcome) covering pain (0-44 points), function (0-47 points), absence of deformity (4 points), and range of motion (5 points). LSMs were based on a repeated measures model fitted with the Harris hip score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.

Time frame:
Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Reported as:
Least squares mean · units on a scale
Harris Hip Score At Each Visit
units on a scalePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 246.6 (43.1 to 50.1)47.7 (43.6 to 51.9)47.3 (43.9 to 50.8)46.5 (43.1 to 50.0)
Week 658.6 (55.1 to 62.1)62.5 (58.3 to 66.7)61.6 (58.1 to 65.0)59.5 (55.9 to 63.0)
Week 1271.2 (67.9 to 74.5)70.9 (67.0 to 74.9)71.7 (68.3 to 75.1)69.6 (66.2 to 72.9)
Week 1674.1 (70.8 to 77.4)76.5 (72.6 to 80.5)76.1 (72.7 to 79.4)72.8 (69.4 to 76.2)
Week 2076.2 (73.0 to 79.3)80.2 (76.4 to 83.9)80.5 (77.4 to 83.6)77.5 (74.3 to 80.7)
Week 2479.0 (76.2 to 81.8)80.3 (76.8 to 83.7)83.0 (80.1 to 85.8)80.1 (77.2 to 83.0)
Week 3680.3 (77.0 to 83.6)82.0 (78.1 to 85.8)86.8 (83.5 to 90.2)83.6 (80.2 to 86.9)
Week 5284.3 (81.3 to 87.4)86.7 (83.0 to 90.3)89.0 (85.9 to 92.1)83.8 (80.7 to 86.9)
SecondaryHip Pain Score at Each Visit

Hip pain was assessed using a visual analog scale (VAS). Participants were asked to rate their pain as a result of the hip fracture on a 100 mm vertical scale with 0 indicating no pain at all and 100 indicating the worst pain they could imagine. LSMs were based on a repeated measures model fitted with hip pain score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.

Time frame:
Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Reported as:
Least squares mean · units on a scale
Hip Pain Score at Each Visit
units on a scalePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 234.3 (28.2 to 40.4)33.1 (25.9 to 40.3)40.3 (34.4 to 46.2)43.0 (37.1 to 48.9)
Week 626.3 (20.8 to 31.7)19.5 (13.1 to 26.0)25.1 (19.7 to 30.4)27.5 (22.1 to 32.9)
Week 1219.4 (14.1 to 24.8)17.8 (11.5 to 24.1)17.5 (12.1 to 22.8)23.7 (18.3 to 29.0)
Week 1618.1 (13.0 to 23.3)13.5 (7.4 to 19.6)16.8 (11.8 to 21.8)17.4 (12.2 to 22.5)
Week 2015.8 (11.2 to 20.4)9.2 (3.8 to 14.7)14.0 (9.5 to 18.5)15.0 (10.5 to 19.6)
Week 2413.8 (9.6 to 18.0)9.1 (4.0 to 14.2)12.7 (8.4 to 17.0)13.1 (8.8 to 17.3)
Week 3614.3 (9.6 to 19.0)10.9 (5.4 to 16.4)11.6 (6.8 to 16.3)10.2 (5.5 to 14.9)
Week 5213.4 (9.2 to 17.7)7.2 (2.1 to 12.3)9.3 (5.1 to 13.5)10.4 (6.2 to 14.6)

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—25/87 (28.7%)31/87 (35.6%)
Romosozumab 70 mg—9/60 (15%)24/60 (40%)
Romosozumab 140 mg—15/89 (16.9%)30/89 (33.7%)
Romosozumab 210 mg—26/89 (29.2%)26/89 (29.2%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventPlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
CellulitisInfections and infestations3/870/601/891/89
Postoperative wound infectionInfections and infestations0/870/600/893/89
OsteoarthritisMusculoskeletal and connective tissue disorders2/870/600/890/89
Acute myocardial infarctionCardiac disorders1/870/601/892/89
PneumoniaInfections and infestations1/870/601/892/89
Hip fractureInjury, poisoning and procedural complications0/870/601/892/89
Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders1/870/600/892/89
Cardiac arrestCardiac disorders0/871/601/891/89
Medical device complicationGeneral disorders0/871/600/891/89
Medical device discomfortGeneral disorders0/871/600/890/89
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
ConstipationGastrointestinal disorders11/876/609/896/89
Back painMusculoskeletal and connective tissue disorders0/877/605/894/89
DiarrhoeaGastrointestinal disorders8/872/602/894/89
Urinary tract infectionInfections and infestations8/874/608/894/89
NauseaGastrointestinal disorders7/874/607/892/89
ArthralgiaMusculoskeletal and connective tissue disorders2/873/606/895/89
HypertensionVascular disorders3/874/605/894/89
Procedural painInjury, poisoning and procedural complications5/871/605/892/89
Pain in extremityMusculoskeletal and connective tissue disorders5/870/600/892/89
OsteoarthritisMusculoskeletal and connective tissue disorders1/873/605/892/89

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Mean76.0 ± 8.676.6 ± 10.375.8 ± 10.176.7 ± 9.576.3 ± 9.5
Age, Customized
Age, Customized(Participants)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
< 65 years108171146
≥ 65 years79527679286
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Female67426455228
Male22182935104
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
White77528170280
Black or African American00011
Hispanic or Latino01102
Asian127111949
Randomization Stratification
Randomization Stratification(Participants)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Intertrochanteric, SHS and 55-75 years139141450
Intertrochanteric, SHS and ≥ 76 years1611161659
Intertrochanteric, IM Nail and 55-75 years1510171658
Intertrochanteric, IM Nail and ≥ 76 years33223433122
Displaced femoral neck and SHS323311
Displaced femoral neck and cancellous screws646521
Undisplaced femoral neck323311
08

Study locations

99 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Pomona, California 91767, United States
  • Research Site
    Aurora, Colorado 80012, United States
  • Research Site
    Denver, Colorado 80204, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Woodbury, Minnesota 55125, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Brooklyn, New York 11220, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Altoona, Pennsylvania 16602, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    State College, Pennsylvania 16801, United States
  • Research Site
    Buenos Aires, C1012AAR, Argentina
  • Research Site
    Buenos Aires, C1419AHN, Argentina
  • Research Site
    Liverpool, New South Wales 2170, Australia
  • Research Site
    Footscray, Victoria 3011, Australia
  • Research Site
    Brugge, 8000, Belgium
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liege, 4000, Belgium
  • Research Site
    Liège, 4020, Belgium
  • Research Site
    Blagoevgrad, 2700, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Red Deer, Alberta T4N 6V7, Canada
  • Research Site
    Cambridge, Ontario N1R 3G2, Canada
  • Research Site
    Guelph, Ontario N1E 4J4, Canada
  • Research Site
    Ottawa, Ontario K1Y 4E9, Canada
  • Research Site
    Toronto, Ontario M5C 1R6, Canada
  • Research Site
    Waterloo, Ontario N2J 1C4, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Quebec, G1J 1Z4, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    København NV, 2400, Denmark
  • Research Site
    Viborg, 8800, Denmark
  • Research Site
    Ã…rhus C, 8000, Denmark
  • Research Site
    Tallinn, 11312, Estonia
  • Research Site
    Tartu, 50410, Estonia
  • Research Site
    Kuopio, 70211, Finland
  • Research Site
    Oulu, 90220, Finland
  • Research Site
    Turku, 20520, Finland
  • Research Site
    Aachen, 52074, Germany
  • Research Site
    Berlin, 12200, Germany
  • Research Site
    Muenchen, 80336, Germany
  • Research Site
    Muenster, 48149, Germany
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Athens, 14561, Greece
  • Research Site
    Larissa, 41110, Greece
  • Research Site
    Patra, 26500, Greece
  • Research Site
    Thessaloniki, 56429, Greece
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    New Territories, Hong Kong
  • Research Site
    Budapest, 1081, Hungary
  • Research Site
    Miskolc, 3526, Hungary
  • Research Site
    Nyiregyhaza, 4400, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Hyderabad, Andhra Pradesh 500 063, India
  • Research Site
    Bangalore, Karnataka 560 054, India
  • Research Site
    Mangalore, Karnataka 575 002, India
  • Research Site
    Nashik, Maharashtra 422 002, India
  • Research Site
    Pune, Maharashtra 411 005, India
  • Research Site
    Pune, Maharashtra 411 044, India
  • Research Site
    Jaipur, Rajasthan 302 022, India
  • Research Site
    Mangalore, 575 001, India
  • Research Site
    Nashik, 422 009, India
  • Research Site
    Firenze, 50139, Italy
  • Research Site
    Milano, 20142, Italy
  • Research Site
    Roma (RM), 00133, Italy
  • Research Site
    Verona, 37126, Italy
  • Research Site
    Riga, 1005, Latvia
  • Research Site
    Valmiera, 4201, Latvia
  • Research Site
    Kaunas, 44320, Lithuania
  • Research Site
    Vilnius, 04130, Lithuania
  • Research Site
    Amsterdam, 1061 AE, Netherlands
  • Research Site
    Amsterdam, 1091 AC, Netherlands
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Haarlem, 2035 RC, Netherlands
  • Research Site
    Nieuwegein, 3435 CM, Netherlands
  • Research Site
    Christchurch, 8022, New Zealand
  • Research Site
    Kraków, 31-826, Poland
  • Research Site
    Lublin, 20-718, Poland
  • Research Site
    Warszawa, 00-739, Poland
  • Research Site
    Warszawa, 03-242, Poland
  • Research Site
    Celje, 3000, Slovenia
  • Research Site
    Izola, 6310, Slovenia
  • Research Site
    Jesenice, 4270, Slovenia
  • Research Site
    Sempeter pri Gorici, 5290, Slovenia
  • Research Site
    Linköping, 581 85, Sweden
  • Research Site
    Lund, 221 85, Sweden
  • Research Site
    Basel, 4031, Switzerland
  • Research Site
    Lausanne, 1011, Switzerland
  • Research Site
    Luzern, 6000, Switzerland
  • Research Site
    Zurich, 8063, Switzerland
  • Research Site
    Barnet, EN5 3DJ, United Kingdom
  • Research Site
    Leeds, LS1 3EX, United Kingdom
  • Research Site
    London, E1 1BB, United Kingdom
  • Research Site
    Newcastle, NE1 4LP, United Kingdom
  • Research Site
    Norwich, NR4 7UY, United Kingdom
09

References and documents

Publications

  • Schemitsch EH, Miclau T, Karachalios T, Nowak LL, Sancheti P, Poolman RW, Caminis J, Daizadeh N, Dent-Acosta RE, Egbuna O, Chines A, Maddox J, Grauer A, Bhandari M. A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures. J Bone Joint Surg Am. 2020 Apr 15;102(8):693-702. doi: 10.2106/JBJS.19.00790. PubMed 31977817 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2010 to primary completion in Jun 2012, 24 months.

Results were first posted in May 2019, 6 years 10 months after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2010
First posted
Mar 5, 2010
StartActual
Jun 20, 2010
Primary completionActual
Jun 30, 2012
CompletionActual
May 10, 2013
Results delay requested
Jan 15, 2014
Results first posted
May 2, 2019
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01081678
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 5, 2010
Start date
Jun 20, 2010
Primary completion
Jun 30, 2012
Completion
May 10, 2013
Results posted
May 2, 2019
Last update
Sep 21, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion